Gilead to buy Ouro Medicines for up to $2.2 billion
#Gilead #Ouro Medicines #acquisition #$2.2 billion #biotech #pharmaceutical #deal #milestone payments
📌 Key Takeaways
- Gilead Sciences is acquiring Ouro Medicines in a deal valued up to $2.2 billion.
- The acquisition aims to expand Gilead's portfolio in the pharmaceutical sector.
- Ouro Medicines is a biotechnology company focused on developing novel therapies.
- The deal includes potential milestone payments that could reach the $2.2 billion total.
🏷️ Themes
Pharmaceutical Acquisition, Biotechnology
Entity Intersection Graph
No entity connections available yet for this article.